.jpg "Sujata M. Bhavnani, PharmD; MS; FIDSA photo")
Executive Vice President
Institute for Clinical Pharmacodynamics
Disclosure(s): A&G Pharma: Grant/Research Support; AiCuris Anti-infective Cures AG: Grant/Research Support; Albany College of Pharmacy and Health Sciences: Grant/Research Support; Albany Medical College: Grant/Research Support; AN2 Therapeutics: Grant/Research Support; Antabio SAS: Grant/Research Support; Apogee Biologics, Inc.: Grant/Research Support; Arcutis Biotherapeutics, Inc.: Grant/Research Support; Aurobac Therapeutics: Advisor/Consultant; B. Braun Medical, Inc.: Grant/Research Support; Basilea Pharmaceutica: Grant/Research Support; Cumberland Pharmaceuticals, Inc.: Grant/Research Support; Debiopharm: Grant/Research Support; Elion Therapeutics, Inc.: Grant/Research Support; Entasis Therapeutics: Grant/Research Support; Excalibur Pharmaceuticals, Inc: Grant/Research Support; Fedora Pharmaceuticals: Grant/Research Support; Genentech: Grant/Research Support; GlaxoSmithKline: Advisor/Consultant; Global Antibiotic Research & Development Partnership: Grant/Research Support; Inotrem: Grant/Research Support; Insmed, Inc.: Grant/Research Support; Institute for Clinical Pharmacodynamics: Ownership Interest; Invivyd, Inc.: Grant/Research Support; Iterum Therapeutics Limited: Grant/Research Support; Kaizen Bioscience: Grant/Research Support; Lassen Therapeutics, Inc.: Grant/Research Support; Matinas Biopharma: Grant/Research Support; Meiji Seika Pharma Co., Ltd.: Grant/Research Support; Melinta Therapeutics: Grant/Research Support; Nabriva Therapeutics AG: Grant/Research Support; National Institutes of Health: Grant/Research Support; Novobiotic Pharmaceuticals LLC.: Grant/Research Support; Paratek Pharmaceuticals, Inc.: Grant/Research Support; Pfizer, Inc.: Grant/Research Support; Praxis Precision Medicines, Inc.: Grant/Research Support; pRxcision, Inc.: Ownership Interest; PTC Therapeutics: Grant/Research Support; PureTech LYT 100, Inc.: Grant/Research Support; Qpex Biopharma: Grant/Research Support; Renibus Therapeutics: Grant/Research Support; Sagimet Biosciences, Inc.: Grant/Research Support; Schrodinger, Inc.: Grant/Research Support; Sfunga Therapeutics: Grant/Research Support; Shionogi, Inc.: Advisor/Consultant, Grant/Research Support; Spero Therapeutics: Grant/Research Support; Spruce Biosciences, Inc.: Grant/Research Support; UCB Biosciences, Inc.: Grant/Research Support; United States Food and Drug Administration: FDA Contract Number: 75F40123C00140; University of Wisconsin: Grant/Research Support; UT Southwestern: Grant/Research Support; VenatoRx Pharmaceuticals, Inc.: Grant/Research Support; Wockhardt Bio AG: Grant/Research Support; Zogenix International: Grant/Research Support
Dr. Bhavnani is the Executive Vice President, Translational Medicine at the Institute for Clinical Pharmacodynamics in Schenectady, New York. Her areas of scientific inquiry primarily involve anti-infective translational science and antimicrobial resistance. Her interest in anti-infective translational science involves the integration of pre-clinical pharmacokinetic-pharmacodynamic data and early clinical pharmacokinetic data to identify dosage regimens that optimize the probability of positive clinical outcomes and minimize the potential of drug toxicities. Results based on these analyses have been presented to regulatory bodies to justify dose selection for clinical trials. Dr. Bhavnani has evaluated exposure-response relationships for antimicrobial agents using pre-clinical and clinical data, the results of which have been used to support decisions for dose selection and interpretive criteria for the in vitro susceptibility testing for numerous new drug applications. Dr. Bhavnani has also undertaken such analyses to support the reappraisal of interpretive criteria for in vitro susceptibility testing of existing antimicrobial agents.
Dr. Bhavnani holds many professional society memberships, including the American Society for Microbiology, the Infectious Disease Society of America, and the International Society of Anti-Infective Pharmacology. She is the author or co-author of over 250 peer-reviewed scientific publications, book chapters, or scientific abstracts and an Associate Editor for Diagnostic Microbiology and Infectious Disease. Dr. Bhavnani is an Executive Committee and voting member for the United States Antimicrobial Susceptibility Test Committee. She has served on the IDWeek Program Planning Committee from 2012 to 2015 and the American Society for Microbiology-European Society of Clinical Microbiology and Infectious Diseases Program Planning Committee from 2017 to 2021.